The link mentioned above between mTOR signaling and abnormal brain metabolism and cerebral blood flow in AD, especially in APOE4 carriers, may add to the rationale of rapamycin clinical trials previously discussed in the paper.133. This evidence concerns the gene APOE and Alzheimer disease.